MX2018012459A - Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. - Google Patents

Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.

Info

Publication number
MX2018012459A
MX2018012459A MX2018012459A MX2018012459A MX2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A
Authority
MX
Mexico
Prior art keywords
dengue
virus
compositions
dengue virus
den
Prior art date
Application number
MX2018012459A
Other languages
English (en)
Inventor
Wallace Derek
Boslego John
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2018012459A publication Critical patent/MX2018012459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Las modalidades en la presente conciernen a composiciones, métodos y usos para inducir una respuesta inmune para los cuatro serotipos de virus de dengue en un niño o adulto joven desde aproximadamente 1 año hasta aproximadamente 20 años de edad. Algunas modalidades conciernen a composiciones que pueden incluir, pero no están limitadas a, quimeras de virus de dengue que, ya sea solas o en combinación con otros constructos, pueden usarse en una composición de vacuna contra los cuatro serotipos de virus de dengue. En ciertas modalidades, las composiciones pueden incluir constructos de más de un serotipo de virus de dengue, tal como virus de dengue-1 (DEN-1), virus de dengue-2 (DEN-2), virus de dengue-3 (DEN-3) y/o virus de dengue-4 (DEN-4), a varias concentraciones o proporciones con el fin de mejorar la protección de infección en niños y adultos jóvenes. En ciertas modalidades, los virus de las formulaciones están limitados a serotipos de virus de dengue. Otras modalidades conciernen a métodos para administrar composiciones inmunogénicas contra virus de dengue que pueden incluir constructos quiméricos de dengue y virus de dengue atenuados, vivos, usando regímenes simples, duales u otros.
MX2018012459A 2016-04-13 2017-04-13 Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. MX2018012459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322167P 2016-04-13 2016-04-13
PCT/IB2017/052160 WO2017179017A1 (en) 2016-04-13 2017-04-13 Compositions and methods of vaccination against dengue virus in children and young adults

Publications (1)

Publication Number Publication Date
MX2018012459A true MX2018012459A (es) 2019-06-06

Family

ID=58671740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012459A MX2018012459A (es) 2016-04-13 2017-04-13 Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.

Country Status (14)

Country Link
US (2) US11007261B2 (es)
EP (1) EP3442571A1 (es)
JP (3) JP2019511533A (es)
KR (1) KR102611235B1 (es)
CN (1) CN109069615A (es)
AU (2) AU2017250696A1 (es)
BR (1) BR112018071087A2 (es)
CA (1) CA3020484A1 (es)
CO (1) CO2018011355A2 (es)
MX (1) MX2018012459A (es)
MY (1) MY192806A (es)
PH (1) PH12018502175A1 (es)
SG (2) SG10201913383RA (es)
WO (1) WO2017179017A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183411A1 (en) * 2013-03-15 2023-05-24 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MX2018012459A (es) * 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
CN117752780A (zh) * 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
SG11202102104SA (en) 2018-09-05 2021-04-29 Takeda Vaccines Inc Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024086681A1 (en) * 2022-10-20 2024-04-25 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0309631B1 (pt) * 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MY184428A (en) 2009-06-01 2021-04-01 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
SG11201500412TA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
JP2016504315A (ja) 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
EP4183411A1 (en) * 2013-03-15 2023-05-24 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
MX2018012459A (es) * 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
SG11202102104SA (en) * 2018-09-05 2021-04-29 Takeda Vaccines Inc Dengue vaccine unit dose and administration thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
BR112018071087A2 (pt) 2019-02-26
JP2022089964A (ja) 2022-06-16
MY192806A (en) 2022-09-09
WO2017179017A1 (en) 2017-10-19
CO2018011355A2 (es) 2018-11-13
AU2017250696A1 (en) 2018-11-22
US20210236620A1 (en) 2021-08-05
EP3442571A1 (en) 2019-02-20
KR20180137514A (ko) 2018-12-27
JP2024071463A (ja) 2024-05-24
CN109069615A (zh) 2018-12-21
CA3020484A1 (en) 2017-10-19
PH12018502175A1 (en) 2019-10-28
SG11201808906RA (en) 2018-11-29
KR102611235B1 (ko) 2023-12-08
AU2018267542A1 (en) 2018-12-13
US20190381163A1 (en) 2019-12-19
JP2019511533A (ja) 2019-04-25
SG10201913383RA (en) 2020-03-30
US11007261B2 (en) 2021-05-18
AU2018267542B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
PH12018502175A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
Khetarpal et al. Dengue fever: causes, complications, and vaccine strategies
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
JP2019511533A5 (es)
PE20140646A1 (es) Vacuna de virus de dengue inactivado
JP2016513970A5 (es)
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
DE60041250D1 (de) Multivalenter dengue-virus impfstoff
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
US9878031B2 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016504315A5 (es)
GEP20237575B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
BRPI0616224B1 (pt) composição farmacêutica
PH12021550785A1 (en) Virus vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
CO2021017772A2 (es) Virus del dengue atenuados
BR0010969A (pt) Vacina polivalente antivìrus da dengue
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
Shen et al. Japanese Encephalitis and Its Vaccines
Buck et al. Animal models of dengue infection and disease.
Ahmad et al. Dengue: Possible strategies for molecular vaccine production